6 min read · updated 2026-10-18
FDA Approval vs. 503A Compounding vs. Research Use Only (2026)
Three labels, three legal categories. What each one means, how 503A compounding works, and why "not FDA approved" does not make two products the same.
Three labels, three legal categories
These labels are often treated as points on one scale. They are not. Each describes a separate legal category with its own rules. An FDA approved drug has completed clinical trials and an FDA review for safety and effectiveness, and is made under current good manufacturing practice. A compounded drug is prepared by a state-licensed pharmacy or physician for one patient, on a prescription, and receives no FDA review before it is dispensed. A research-use-only material is supplied for laboratory, in vitro and preclinical research, and is not for human or veterinary use.
Why not FDA approved does not make two products the same
Compounded drugs and research-use-only materials are both not FDA approved, so they are often grouped together. They are not interchangeable. Compounding is a lawful route to an individual patient, through a prescriber and a licensed pharmacy overseen by a state pharmacy board. Research-use-only materials sit outside medical channels entirely, and their labeling describes laboratory use only. Sharing the phrase not FDA approved says nothing about which rules apply.
How 503A compounding works
Section 503A of the Federal Food, Drug, and Cosmetic Act lets a pharmacy compound with a bulk drug substance through one of three pathways: the substance is a component of an FDA approved drug, it has a USP or National Formulary monograph, or it appears on the FDA 503A bulks list. Most research peptides meet neither of the first two, so the bulks list is their only route. While that list is built, FDA sorts nominated substances into interim categories. Category 1 substances may be compounded under enforcement discretion. Category 2 covers substances FDA has flagged for significant safety concerns.
Where peptides stand in 2026
In 2026, FDA reopened its review of several peptides for pharmacy compounding, and an advisory committee recommended six for the 503A bulks list. A recommendation is not a decision, and none of these steps makes a peptide FDA approved or changes the rules for research-use material. The full timeline and the status of each compound are kept on two dedicated pages.
What research use only means, and what it does not
Research use only describes intended use: laboratory, in vitro and preclinical research. It is not a loophole. FDA judges intended use from the whole context, including a seller website, its marketing, and what is sold alongside the material, and in 2026 it rejected research-use-only disclaimers from sellers whose websites pointed toward human use. A research-use-only label should therefore come with no dosing guidance, no administration instructions and no therapeutic claims, and with documentation instead: a certificate of analysis for the specific lot.
How to tell which label you are looking at
An FDA approved drug carries an approved product name, a National Drug Code (NDC) number and full prescribing information. A compounded drug carries a pharmacy label with a patient name, a prescriber and the dispensing pharmacy. A research-use-only material carries a lot number, a research-use statement, and a certificate of analysis that matches that lot.
Sources
Regulatory facts on this page were checked against these sources on 18 October 2026.
Frequently asked
Are research peptides FDA approved?
No. Research-use-only peptides are supplied for laboratory research and are not FDA approved for any use in people or animals. They are not for human or veterinary use.
Is a compounded peptide FDA approved?
No. Compounded drugs are not FDA approved. FDA does not review them for safety, effectiveness or quality before a pharmacy dispenses them.
Did the July 2026 advisory committee vote approve these peptides?
No. The committee recommended adding six peptides to the 503A bulks list. That would allow pharmacy compounding under Section 503A. It would not make them FDA approved drugs.
What would the 2026 interim access policy do?
Its terms had not been published as of October 2026. Reporting describes it as an assurance that pharmacies would not be targeted for compounding certain peptides while permanent rules are written.
What is the difference between 503A and research use only?
A 503A pharmacy compounds a drug for one patient on a prescription, under state pharmacy board oversight. Research-use-only material is supplied for laboratory work outside medical channels and is not for human or veterinary use.
See the practice, not just the principle
Every lot we release is published in full — assay, method, and measured result — and the record stays online after the lot sells out.
Open the COA library